Logotipo de Valence
populares
Iniciar sesión
Loading data for BNTX — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

BioNTech SE

NasdaqGS: BNTX · Precio en tiempo real · USD
114.05
+1.23 (1.09%)
Al cierre: Aug 26, 2026, 2:15 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

BioNTech SE (BNTX): cotización, análisis y datos

1.09%

No hay datos disponibles

Precio de compra82.96
Capitalización de mercado28.46B
Ingresos (TTM)2.65B
Beneficio neto (TTM)-1.69B
1.28
-7.84
n/a
-19.97
P/B (TTM)1.37
P/S (TTM)10.74
Fecha de resultadosNov 3, 2026
Precio de venta145.47
Volumen1,358,860
Volumen medio (20D)1,162,246
Abierto113.99
Anterior Cerrar112.82
Rango del día113.41 - 116.87
Rango de 52 semanas79.52 - 124.00
analistan/a
Precio objetivon/a
Dividendosn/a
Fecha ex dividendo2 jun 2022

Acerca de BNTX

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirt...

[Leer más]
Industria Biotechnology
Sector Healthcare
IPO Fecha Oct 10, 2019
Empleados 7,807
Bolsa de Valores NasdaqGS
Símbolo bursátil BNTX
Sitio web https://www.biontech.de
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de BioNTech SE fueron 2.87B, un aumento de 4.32% en comparación con 2.75B del año anterior. Las ganancias fueron -1.14B, un aumento de 70.77%.

Estados financieros

Sorpresa de resultados

BioNTech SE ha publicado sus resultados trimestrales en Aug 4, 2026:
  • Ingresos de $105.6M falla las estimaciones por $0, con -59.51% Disminución interanual.
  • EPS de -2.22 falla las estimaciones por -0.14, con -38.75% Disminución interanual.

Próxima publicación de resultados

Está previsto que BioNTech SE publique sus resultados el Nov 3, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar
news image

1 día hace · 24/7 Wall St.

Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?

Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the entire post-K...

news image

1 día hace · 24/7 Wall St.

Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name?

Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector. Something broke between these two names, and figu...

news image

1 día hace · 24/7 Wall St.

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.

Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of t...

news image

2 días hace · 24/7 Wall St.

Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips

Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or the beginning of a painful unwind for latec...

news image

2 días hace · MT Newswires

European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading

European equities traded in the US as American depositary receipts started the week slightly lower l

Página 1 de 2